These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9292008)

  • 21. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
    Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
    Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactivities of polyclonal and monoclonal antibodies raised to the major capsid protein of human papillomavirus type 16.
    Patel D; Shepherd PS; Naylor JA; McCance DJ
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():69-77. PubMed ID: 2543739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts.
    Carter JJ; Hagensee MB; Lee SK; McKnight B; Koutsky LA; Galloway DA
    Virology; 1994 Mar; 199(2):284-91. PubMed ID: 7510082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
    Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
    J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
    Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope mapping of the human papillomavirus type 16 E4 protein by means of synthetic peptides.
    Suchánková A; Krchnák V; Vágner J; Hamsíková E; Krcmár M; Ritterová L; Vonka V
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():429-32. PubMed ID: 1371544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids.
    Wang ZH; Kjellberg L; Abdalla H; Wiklund F; Eklund C; Knekt P; Lehtinen M; Kallings I; Lenner P; Hallmans G; Mählck CG; Wadell G; Schiller J; Dillner J
    J Infect Dis; 2000 Feb; 181(2):456-62. PubMed ID: 10669326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
    Marais D; Rose RC; Williamson AL
    J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
    Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.
    Nindl I; Benitez-Bribiesca L; Berumen J; Farmanara N; Fisher S; Gross G; Lopez-Carillo L; Müller M; Tommasino M; Vazquez-Curiel A
    Arch Virol; 1994; 137(3-4):341-53. PubMed ID: 7524466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
    Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
    Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
    Strickler HD; Schiffman MH; Eklund C; Glass AG; Scott DR; Sherman ME; Wacholder S; Kurman RJ; Manos MM; Schiller JT; Dillner J
    Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):183-8. PubMed ID: 9138661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasia using an in vitro assay.
    Leiserowitz GS; Hall KS; Foster CA; Hitchcock ME; Christensen ND; Heim K; Smith LH
    Gynecol Oncol; 1997 Aug; 66(2):295-9. PubMed ID: 9264579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
    Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
    Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides.
    Lim PS; Jenson AB; Cowsert L; Nakai Y; Lim LY; Jin XW; Sundberg JP
    J Infect Dis; 1990 Dec; 162(6):1263-9. PubMed ID: 1700026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups.
    Heim K; Christensen ND; Hoepfl R; Wartusch B; Pinzger G; Zeimet A; Baumgartner P; Kreider JW; Dapunt O
    J Infect Dis; 1995 Aug; 172(2):395-402. PubMed ID: 7542685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls.
    Luxton JC; Rose RC; Coletart T; Wilson P; Shepherd PS
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():917-23. PubMed ID: 9129666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles.
    Tachezy R; Hamsíková E; Hájek T; Mikysková I; Smahel M; Van Ranst M; Kanka J; Havránková A; Rob L; Guttner V; Slavík V; Anton M; Kratochvíl B; Kotrsová L; Vonka V
    J Med Virol; 1999 Aug; 58(4):378-86. PubMed ID: 10421405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.